{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:21:28Z","timestamp":1791472888426,"version":"4.3.4"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO\u2010DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101RA) use on the treatment effect of finerenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with type 2 diabetes, urine albumin\u2010to\u2010creatinine ratio (UACR) 30\u20105000\u2009mg\/g and estimated glomerular filtration rate 25\u2010&lt;75\u2009ml\/min per 1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      receiving optimized renin\u2010angiotensin system blockade were randomized to finerenone or placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 5674 patients analysed, overall, 394 (6.9%) received GLP\u20101RAs at baseline. A reduction in UACR with finerenone was observed with or without baseline GLP\u20101RA use; ratio of least\u2010squares means 0.63 (95% confidence interval 0.56, 0.70) with GLP\u20101RA use and 0.69 (95% confidence interval 0.67, 0.72) without GLP\u20101RA use (\n                      <jats:italic>p<\/jats:italic>\n                      value for interaction .20). Finerenone also significantly reduced the primary kidney (time to kidney failure, sustained decrease in estimated glomerular filtration rate \u226540% from baseline, or renal death) and key secondary CV outcomes (time to CV death, non\u2010fatal myocardial infarction, non\u2010fatal stroke, or hospitalization for heart failure) versus placebo, with no clear difference because of GLP\u20101RA use at baseline (\n                      <jats:italic>p<\/jats:italic>\n                      value for interaction .15 and .51 respectively) or any time during the trial. The safety profile of finerenone was similar between subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This exploratory subgroup analysis suggests that finerenone reduces UACR in patients with or without GLP\u20101RA use at baseline, and the effects on kidney and CV outcomes are consistent irrespective of GLP\u20101RA use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14558","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T03:24:39Z","timestamp":1632799479000},"page":"125-134","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by\n                    <scp>GLP\u20101RA<\/scp>\n                    treatment: A subgroup analysis from the\n                    <scp>FIDELIO\u2010DKD<\/scp>\n                    trial"],"prefix":"10.1111","volume":"24","author":[{"given":"Peter","family":"Rossing","sequence":"first","affiliation":[{"name":"Steno Diabetes Center Copenhagen  Gentofte Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Richard L. Roudebush VA Medical Center and Indiana University  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies German Centre for Cardiovascular Research Partner Site Berlin, Charit\u00e9 Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Michigan School of Medicine  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Cardiorenal Translational Laboratory and Hypertension Unit Institute of Research imas12  Madrid Spain"},{"name":"CIBER\u2010CV Hospital Universitario 12 de Octubre  Madrid Spain"},{"name":"Faculty of Sport Sciences European University of Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam","family":"Amod","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Life Chatsmed Garden Hospital and Nelson R. Mandela School of Medicine, University of KwaZulu\u2010Natal  Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[{"name":"Clinique Ambroise Par\u00e9 Neuilly\u2010sur\u2010Seine Centre de Recherches des Cordelier, Universit\u00e9 Paris Diderot  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development Bayer AG  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lage","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development Bayer SA  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[{"name":"Data Science and Analytics Bayer PLC  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Chicago Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FIDELIO\u2010DKD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040947"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060233"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00967"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00798-x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01154-w"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-00367-2"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30313-2"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.08.036"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"issue":"45","key":"e_1_2_9_17_1","first-page":"S1","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","journal-title":"Kidney Int"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.016"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.02.030"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy120"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0944"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503713"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30314-0"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.723270"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60595-4"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011489"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708379"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080830"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503712"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12651"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"e_1_2_9_36_1","volume-title":"Prescribing Information","author":"KERENDIA","year":"2021"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14558","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:20:00Z","timestamp":1761891600000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/dom.14558"],"URL":"https:\/\/doi.org\/10.1111\/dom.14558","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review7","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14558\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"2021-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}